

Pemphigus Vulgaris (Immunology) - Drugs in Development, 2021

<https://marketpublishers.com/r/PE95B00D7800EN.html>

Date: September 2021

Pages: 88

Price: US\$ 2,000.00 (Single User License)

ID: PE95B00D7800EN

Abstracts

Pemphigus Vulgaris (Immunology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris - Drugs In Development, 2021, provides an overview of the Pemphigus Vulgaris (Immunology) pipeline landscape. Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, skin blisters that come and go; the blisters always occur near the surface of the skin and oozing, crusting, or peeling at the blister site.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pemphigus Vulgaris - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Pemphigus Vulgaris (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery

stages are 1, 1, 3, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pemphigus Vulgaris (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris (Immunology).

The pipeline guide reviews pipeline therapeutics for Pemphigus Vulgaris (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pemphigus Vulgaris (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pemphigus Vulgaris (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris (Immunology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pemphigus Vulgaris (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pemphigus Vulgaris (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Pemphigus Vulgaris - Overview
Pemphigus Vulgaris - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pemphigus Vulgaris - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pemphigus Vulgaris - Companies Involved in Therapeutics Development
Argenx SE
Biogen Inc
BioXpress Therapeutics SA
Cabaletta Bio Inc
Daewoong Pharmaceutical Co Ltd
HanAll Biopharma Co Ltd
iBio Inc
Octagon Therapeutics Inc
Pharmapraxis
Topas Therapeutics GmbH
Pemphigus Vulgaris - Drug Profiles
batoclimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-212525 - Drug Profile
Product Description
Mechanism Of Action

R&D Progress

efgartigimod alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target DSG1 and DSG3 for Mucocutaneous Pemphigus Vulgaris -

Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target DSG3 for Pemphigus Vulgaris - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OW-177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biobetter - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPM-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pemphigus Vulgaris - Dormant Projects

Pemphigus Vulgaris - Discontinued Products

Pemphigus Vulgaris - Product Development Milestones

Featured News & Press Releases

Aug 18, 2021: Cabaletta Bio reports clinical data from the second dose cohort in DesCAARTes trial in patients with mPV

May 03, 2021: Cabaletta Bio reports acute safety data from the first dose cohort in DesCAARTes trial

Dec 08, 2020: Cabaletta Bio announces first patient dosed in Landmark DesCAARTes trial of DSG3-CAART for treatment of mucosal-dominant pemphigus vulgaris

Aug 25, 2020: Cabaletta Bio announces publication of comprehensive preclinical study results for DSG3-CAART in pemphigus vulgaris

May 06, 2020: Cabaletta Bio receives FDA Fast Track Designation for DSG3-CAART for the treatment of Mucosal Pemphigus Vulgaris

Jan 29, 2020: FDA grants DSG3-CAART orphan drug designation for the treatment of pemphigus vulgaris

Dec 18, 2019: Topas Therapeutics announces first patient enrolled in phase 1 trial with TPM203 in pemphigus vulgaris

Oct 14, 2019: Roche's Rituxan outperforms MMF in pemphigus vulgaris study

Oct 01, 2019: Cabaletta Bio receives IND clearance from FDA to initiate first clinical trial of DSG3-CAART in patients with Mucosal Pemphigus Vulgaris

Jun 12, 2019: Phase III PEMPHIX study showed that Genentech's Rituxan (Rituximab) is superior to standard of care in achieving sustained remission in patients with Pemphigus Vulgaris

Mar 15, 2019: EC approves Roche's MabThera for pemphigus vulgaris

Jan 31, 2019: CHMP recommended extension of indication for Mabthera

Dec 12, 2018: Cell therapy industry pioneer, Gwendolyn Binder, Ph.D., to join Cabaletta Bio leadership team

Jul 24, 2018: argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation

Jun 20, 2018: argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Pemphigus Vulgaris, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pemphigus Vulgaris - Pipeline by Argenx SE, 2021
Pemphigus Vulgaris - Pipeline by Biogen Inc, 2021
Pemphigus Vulgaris - Pipeline by BioXpress Therapeutics SA, 2021
Pemphigus Vulgaris - Pipeline by Cabaletta Bio Inc, 2021
Pemphigus Vulgaris - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co Ltd, 2021
Pemphigus Vulgaris - Pipeline by iBio Inc, 2021
Pemphigus Vulgaris - Pipeline by Octagon Therapeutics Inc, 2021
Pemphigus Vulgaris - Pipeline by Pharmapraaxis, 2021
Pemphigus Vulgaris - Pipeline by Topas Therapeutics GmbH, 2021
Pemphigus Vulgaris - Dormant Projects, 2021
Pemphigus Vulgaris - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Pemphigus Vulgaris, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Pemphigus Vulgaris (Immunology) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/PE95B00D7800EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PE95B00D7800EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970